Ann Navar, MD, PhD, FAHA, FACC, FASPC

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Esperion an Amgen
    Topic:
    research support to UTSW-cardiovascular epidemiology and prevention
    Date added:
    Date updated:
    02/09/2026
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Amgen, Arrowhead, Bayer, Eli Lilly, Esperion, Janssen, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche, Silence Therapeutics, and Pfizer
    Topic:
    consulting fees-cardiovascular research
    Date added:
    Date updated:
    02/09/2026
Return to 102 Cardiology Clinical Conference (FY26) "The 2026 AHA/ACC Dyslipidemia Guideline: What Cardiologists Need to Know" & "The Tricuspid Valve in 2026: From Clinical Neglect to Precision Interventions" (052026)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.